| Southwest Austin Foot & Ankle Clinic, Pllc | |
|
5625 Eiger Rd Ste 110, Austin, TX 78735-8978 | |
| (512) 447-4122 | |
| (512) 614-4139 |
| Full Name | Southwest Austin Foot & Ankle Clinic, Pllc |
|---|---|
| Type | Facility |
| Speciality | Podiatrist - Foot & Ankle Surgery |
| Location | 5625 Eiger Rd Ste 110, Austin, Texas |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659708220 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213ES0103X | Podiatrist - Foot & Ankle Surgery | (* (Not Available)) | Primary |
| Provider Name | Liza Chabokrow |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1477733996 PECOS PAC ID: 3577605419 Enrollment ID: I20100115000211 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Provider Name | Kim Le Dao |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1750722997 PECOS PAC ID: 3678868767 Enrollment ID: I20160829001918 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Provider Name | Vi Hoang Nguyen |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1497132401 PECOS PAC ID: 4880943232 Enrollment ID: I20180820000686 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Provider Name | Binh Ta |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1336512508 PECOS PAC ID: 8628321452 Enrollment ID: I20181025000385 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Provider Name | Katherine Marie Adams |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1972954782 PECOS PAC ID: 5698003655 Enrollment ID: I20190829000085 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Provider Name | Vanatius Nketi Babila Tita |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1114416807 PECOS PAC ID: 6608270798 Enrollment ID: I20210811003801 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Provider Name | Jaya Rajagopalan |
|---|---|
| Provider Type | Practitioner - Podiatry |
| Provider Identifiers | NPI Number: 1417448994 PECOS PAC ID: 9830594845 Enrollment ID: I20210828000044 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Southwest Austin Foot & Ankle Clinic, Pllc 5625 Eiger Rd Ste 110, Austin, TX 78735-8978 Ph: (512) 447-4122 | Southwest Austin Foot & Ankle Clinic, Pllc 5625 Eiger Rd Ste 110, Austin, TX 78735-8978 Ph: (512) 447-4122 |
News Archive
Asthma affects almost 1 in 10 children in the U.S. and is a leading cause of emergency room visits and hospitalizations in preschoolers. According to new research from Duke Health and collaborators, symptoms may be worse for children ages 2 to 5 who are overweight.
New insights on how subunits of the influenza virus polymerase co-evolve to ensure efficient viral RNA replication are provided by a study published October 3 in the open-access journal PLOS Pathogens by Nadia Naffakh of the Institut Pasteur, and colleagues. As the authors note, the findings could lead to novel strategies for antiviral drug development.
Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.
VITAS, the nation's leading hospice provider, is now serving patients with life-limiting diagnoses and their families in the greater Columbus area, including those in Delaware, Fairfield, Franklin, Licking, Madison, Pickaway and Union counties. VITAS also provides quality, compassionate end-of-life care in Ohio to patients and families in Cleveland, Cincinnati and Dayton.
ACCESS PHARMACEUTICALS, INC. today provided an update on its European commercial launch of MuGard, an FDA approved treatment for oral mucositis, a debilitating side effect of radiation treatment and chemotherapy.
› Verified 3 days ago
Capital Foot & Ankle Surgeons Of Austin, Pllc Podiatrist Medicare: Medicare Enrolled Practice Location: 900 E 30th St, 311, Austin, TX 78705 Phone: 512-474-6666 Fax: 512-474-6668 | |
Mr. Joseph Harold Snowden, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 911 W 38th St Ste 300, Austin, TX 78705 Phone: 512-439-1000 | |
Vikas A Godhania, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 6811 Austin Center Blvd # 300, Austin, TX 78731 Phone: 512-346-8888 Fax: 512-344-0365 | |
J Michael Valenza, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 5656 Bee Cave Rd, Ste D204, Austin, TX 78746 Phone: 512-327-9251 Fax: 512-327-9742 | |
Angela L Drury Pc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2312 Western Trails, Suite 103, Austin, TX 78745 Phone: 512-382-0773 Fax: 512-382-0072 | |
Dr. Anne Compeau Ames, D.P.M. Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 1301 W 38th St, Suite 707, Austin, TX 78705 Phone: 512-407-8188 Fax: 512-459-1190 | |
Angela L Drury, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2312 Western Trails Blvd, Suite 103, Austin, TX 78745 Phone: 512-382-0773 Fax: 512-382-0772 |